Value of follow-up diagnostic radioiodine scans in differentiated thyroid cancer

被引:1
|
作者
Kraus, Teresa [1 ]
Shengelia-de Lange, Natalia [2 ]
Einspieler, Holger [1 ]
Hacker, Marcus [1 ]
Haug, Alexander [1 ]
Kretschmer-Chott, Elisabeth [1 ]
Karanikas, Georgios [1 ]
机构
[1] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Div Nucl Med, Vienna, Austria
[2] Tbilisi State Med Univ, Div Nucl Med, Tbilisi, Georgia
关键词
thyroid cancer; thyroglobulin; follow-up; diagnostic radioiodine whole-body scan; LOW-RISK PATIENTS; SERUM THYROGLOBULIN LEVELS; WHOLE-BODY SCAN; NECK ULTRASONOGRAPHY; MANAGEMENT GUIDELINES; CARCINOMA; PAPILLARY; ABLATION; SCINTIGRAPHY; MODALITIES;
D O I
10.1530/EC-24-0007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The most important part of the follow-up of differentiated thyroid carcinoma (DTC) is the measurement of serum thyroglobulin (Tg). An increase of Tg levels indicates likely tumor recurrence. According to the guidelines of the European Society of Medical Oncology (ESMO), the follow-up should consist of serum Tg assays and a neck ultrasound, while the American Thyroid Association (ATA) recommends serum Tg assays, neck ultrasounds, and a diagnostic radioiodine whole-body scan (WBS) if non-stimulated Tg is greater than 10 ng/mL or if Tg is rising. This study questions the necessity of a diagnostic WBS in patients with low stimulated Tg levels during the initial follow-up. Design: This study is a retrospective data analysis. Methods: The data of 185 patients, who were in regular treatment and aftercare between 2015 and 2018 at the Department of Nuclear Medicine in Vienna, as well as the data of 185 patients who were treated in Tbilisi between 2015 and 2019, were analyzed. Results: There was a highly significant relationship between low stimulated Tg levels (<0.5 ng/mL) and the outcome of the diagnostic WBS at the first follow-up (chi (2 )= 14.7, P < 0.001). In total, 31 out of 370 patients (8.4%) had positive findings in the diagnostic WBS. Seventy-five of 370 patients (19.74%) had stimulated Tg levels >0.5 ng/mL. Conclusion: Our data suggest that the first follow-up, 4-12 months after the initial therapy of DTC, including the measurement of basal and stimulated Tg levels and Tg antibody levels, does not mandate a diagnostic WBS on all patients. Significance statement: In this study, we examined the still commonly used routine diagnostic radioiodine whole-body scan in the first follow-up of patients with differentiated thyroid carcinoma. We questioned the necessity of the scan in patients with low stimulated thyroglobulin levels. Therefore, we combined retrospective data from the University Hospital in Vienna and in Tbilisi to analyze 370 patients. We were able to demostrate a highly significant relationship between low stimulated thyroglobulin levels (<0.5 ng/mL) and the outcome of the diagnostic scan at the first follow-up (chi = 14.7, P < 0.001).
引用
收藏
页数:6
相关论文
共 50 条
  • [41] THYROGLOBULIN, I-131 WHOLE-BODY SCANS AND RISK-FACTORS IN THE FOLLOW-UP OF DIFFERENTIATED THYROID-CANCER
    BERDING, G
    HUFNER, M
    GEORGI, P
    NUKLEARMEDIZIN, 1992, 31 (01) : 32 - 37
  • [42] Clinical guidance for radioiodine refractory differentiated thyroid cancer
    Gild, Matti L.
    Topliss, Duncan J.
    Learoyd, Diana
    Parnis, Francis
    Tie, Jeanne
    Hughes, Brett
    Walsh, John P.
    McLeod, Donald S. A.
    Clifton-Bligh, Roderick J.
    Robinson, Bruce G.
    CLINICAL ENDOCRINOLOGY, 2018, 88 (04) : 529 - 537
  • [43] Follow-up Care for differentiated Thyroid Carcinoma
    Eilsberger, Friederike
    Pfestroff, Andreas
    Librizzi, Damiano
    Luster, Markus
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2020, 145 (17) : 1236 - 1244
  • [44] Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy
    Zhao, Teng
    Liang, Jun
    Li, Tianjun
    Gao, Wen
    Lin, Yansong
    CHINESE JOURNAL OF CANCER RESEARCH, 2017, 29 (03) : 213 - 222
  • [45] Is there survival benefit from life-long follow-up after treatment for differentiated thyroid cancer?
    Garas, George
    Jarral, Omar
    Tolley, Neil
    Palazzo, Fausto
    Athanasiou, Thanos
    Zacharakis, Emmanouil
    INTERNATIONAL JOURNAL OF SURGERY, 2013, 11 (02) : 116 - 121
  • [46] Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the "con" point of view
    Lamartina, Livia
    Cooper, David S.
    ENDOCRINE, 2015, 50 (01) : 67 - 71
  • [47] Usefulness of neck ultrasonography in the follow-up of patients with differentiated thyroid cancer
    Rosario, Pedro W.
    Tavares Junior, Wilson C.
    Biscolla, Rosa Paula M.
    Purisch, Saulo
    Maciel, Rui M. B.
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2007, 51 (04) : 593 - 600
  • [48] The value of thyroperoxidase as a prognostic factor for differentiated thyroid cancer - A long-term follow-up study
    Caballero Y.
    López-Tomassetti E.M.
    Favre J.
    Santana J.R.
    Cabrera J.J.
    Hernández J.R.
    Thyroid Research, 8 (1)
  • [49] Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial
    Dong, Ping
    Qu, Yuan
    Yang, Liu
    Xiao, Liu
    Huang, Rui
    Li, Lin
    CLINICAL ENDOCRINOLOGY, 2021, 95 (05) : 782 - 789
  • [50] The Role of Routine Diagnostic Radioiodine Whole-Body Scintigraphy in Patients with High-Risk Differentiated Thyroid Cancer
    de Meer, Siegrid G.
    Vriens, Menno R.
    Zelissen, Pierre M.
    Rinkes, Inne H. Borel
    de Keizer, Bart
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (01) : 56 - 59